A look at ABBV technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 53.42 point. Its trading volume has added 610593 shares compared to readings over the past three months as it recently exchanged 6950593 shares. This means there is improved activity from short-term traders as per session, its average trading volume is 6340000 shares, and this is 1.1 times the normal volume.
AbbVie Inc. (NYSE:ABBV) dipped by -4.87% over the past three months which led to its overall six-month decrease to stand at -9.43%. The equity price rose 3.27% this week, a trend that has led to both investors and traders taking note of the stock. A look at its monthly performance shows that its shares have recorded a 13.81% gain over the past 30 days. Over the past 12 months the stock has embarked on a drop that has seen it decline -4.9% and is now down by -6.37% since start of this year.
The shares of AbbVie Inc. dropped by -28.05% or -$35.31 from its last recorded high of $125.86 which it attained on January 26 to close at $90.55 per share. Over the past 52 weeks, the shares of AbbVie Inc. has been trading as low as $77.5 before witnessing a massive surge by 16.84% or $13.05. This price movement has led to the ABBV stock receiving more attention and has become one to watch out for. It dipped by -3.32% on Tuesday and this got the market worried. The stock’s beta now stands at 1.66 and when compared to its 200-day moving average and its 50-day moving average, ABBV price stands -6.28% below and 2.06% above respectively. Its average daily volatility for this week is 3.4% which is more than the 3.19% recorded over the past month.
Experts from research firms are bullish about the near-term performance of AbbVie Inc. (ABBV) with most of them predicting a $100.58 price target on a short-term (12 months) basis. The average price target by the analysts will see a 11.08% rise in the stock and would lead to ABBV’s market cap to surge to $151.88B. The stock has been rated an average 2.6, which roughly stands towards the bearish end of the spectrum. Reuters looked into the 20 analysts that track AbbVie Inc. (NYSE:ABBV) and find out that 9 of them rated it as a Hold. 8 of the 11 analysts rated it as a Buy or a Strong Buy while 3 advised investors to desist from buying the stock or sell it if they already possess it.
The price of KLA-Tencor Corporation (NASDAQ:KLAC) currently stands at $95.92 after it went down by $-5.23 or -5.17% and has found a strong support at $94.47 a share. If the KLAC price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $93.02 mark would also be bad for the stock as it means that the stock would plunge by 3.02% from its current position. However, if the stock price is able to trade above the resistance point around $98.63, then it could likely surge higher to try and break the upward resistance which stands at $101.34 a share. Its average daily volatility over the past one month stands at 3.38%. The stock has plunged by 0.2% from its 52-weeks high of $95.73 which it reached on Mar. 13, 2018. In general, it is 11.81% above its 52-weeks lowest point which stands at $84.59 and this setback was observed on Oct. 29, 2018.
Analysts have predicted a price target for KLA-Tencor Corporation (KLAC) for 1 year and it stands at an average $121.14/share. This means that it would likely increase by 26.29% from its current position. The current price of the stock has been moving between $95.73 and $99.89. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $98. On the other hand, one analyst is super bullish about the price, setting a target as high as $148.
The KLAC stock Stochastic Oscillator (%D) is at 84.55%, which means that it is currently overbought and its prices could dip very soon. The shares P/S ratio stands at 3.58 which compares to the 2.2 recorded by the industry or the 123.63 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 10.52, which is lower than the 11.32 multiple of 12-month price-earnings (P/E). The company’s earnings have gone up, with a quarterly increase rate of 18.8% over the past five years.
Analysts view KLA-Tencor Corporation (NASDAQ:KLAC) as a Buy, with 2 consensus rating. Reuters surveyed 13 analysts that follow KLAC and found that 3 of those analysts rated the stock as a Hold. The remaining 10 were divided, with 10 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying KLA-Tencor Corporation (KLAC) shares or sell it if they already own it.